" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemod… (NCT06983756) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "
66 participantsStarted 2025-06-01
Plain-language summary
The primary aim of this study is to investigate the association between metabolic syndrome and erythropoietin resistance in patients with End-Stage Kidney Disease (ESKD).
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients (and replacements) will be randomly selected by a raffle.
* All participants should be 18 years of age or older and agree to participate in the study after due clarification.
* Patients with end stage kidney disease (ESKD) on regular hemodialysis for more than 3 months.
Exclusion Criteria:
* \- Patients with neoplasm, severe cardiovascular, cerebrovascular and liver diseases.
* Females with polycystic ovarian syndrome, those on hormonal replacement therapy and pregnant women.
* Patients with infection or autoimmune diseases.